Michal Merdas

Michal Merdas

Auto-generated profile, based on publicly available information

Michal Merdas

Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2018 in Archivum Immunologiae et Therapiae Experimentalis
Verified
Journal Article
Open access
PDF file
MCMarzena Ciechomska
Marzena Ciechomska
KBKrzysztof Bonek
Krzysztof Bonek
MMMichal Merdas
Michal Merdas
PZPatryk Zarecki
Patryk Zarecki
JSJerzy Swierkot
Jerzy Swierkot
WMWlodzimierz Maslinski
Wlodzimierz Maslinski
In this study, we analysed the expression level of sera circulating miRNA-5196 in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) patients before and after tumor necrosis factor (TNF)-α therapy as biomarkers predicting positive treatment outcome. We enrolled 10 RA patients, 13 AS patients, and 12 healthy individuals in the study. The expression of miRNA-5196 was measured by real-time polymerase chain reaction before and after anti-TNF-α therapy. Disease activity of RA patients was assessed using disease activity score 28 (DAS28), whereas ankylosing spondylitis DAS (ASDAS) was used in AS patients. MiRNA-5196 expression was significantly higher in patients with RA and AS before TNF-α therapy than in those following anti-TNF-α therapy and healthy controls. Changes in miRNA-5196 expression positively correlated with delta DAS28 or delta ASDAS, respectively, following TNF-α therapy. In contrast, changes in C-reactive protein (CRP) levels in RA and AS patients did not positively correlate with DAS28 or ASDAS changes. Receiver-operating characteristic analysis showed better diagnostic accuracy of miRNA-5196 expression both in RA (area under curve (AUC) = 0.87, p = 0.055) and AS patients (AUC = 0.90, p = 0.050) compared to CRP levels in RA (AUC = 0.75, p = 0.201) and AS patients (AUC = 0.85, p = 0.086) upon biologic therapy treatment. Finding novel biomarkers, including miRNA-5196 which allow to predict and monitor anti-TNF-α response, would be of clinical value especially during the early phase of RA or AS development.

9 July 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
JBJean Berthelet
Jean Berthelet
VWVerena C. Wimmer
Verena C. Wimmer
HWHolly J Whitfiled
Holly J Whitfiled
ASAntonin Serrano
Antonin Serrano
TBThomas Boudier
Thomas Boudier
Delphine MerinoDelphine Merino
Delphine Merino
Optical barcoding reveals enhanced TNFα activation and polyclonality in lung, but not liver, metastases from breast cancer.

21 June 2017 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
MCMarzena Ciechomska
Marzena Ciechomska
PZPatryk Zarecki
Patryk Zarecki
MMMichal Merdas
Michal Merdas
JSJerzy Swierkot
Jerzy Swierkot
EMEwa Morgiel
Ewa Morgiel
KBKatarzyna Bogunia-Kubik
Katarzyna Bogunia-Kubik

1 March 2015 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
MCMarzena Ciechomska
Marzena Ciechomska
SOSteven O'reilly
Steven O'reilly
MMM Merdas
M Merdas
PZPatryk Zarecki
Patryk Zarecki
JŚJerzy Świerkot
Jerzy Świerkot
JLJm van Laar
Jm van Laar
Background and objectives To investigate whether epigenetic changes induced by 3’deazaneplanocin - DZNep and TLR signalling pathway can modulate monocytes to produce tissue-inhibitor of metalloproteinase-1 (TIMP-1) via Fra2 (Fos-related antigen 2) activity, a novel downstream mediator promoting fibrogenesis. Methods AP-1 and TIMP-1 expression following TLR8 treatment was measured by qRT-PCR in monocytes from Systemic sclerosis (SSc) patients (n = 13) and healthy controls (HC) (n = 13). TIMP-1 promoter activity was measured in U397 monocytic cell line using luciferase reporter assay. The effect of DZNep treatment on inhibition of tri-methylation of lysine 27 on histone 3 was analysed by Western Blot. Expression of TIMP-1 and Fra2 was determined in response to DZNep. The functional effect of TLR8 and DZNep-treated HC monocytes was studied on dermal fibroblasts’ trans-differentiation. Results Increased Fra2 and TIMP-1 expression was correlated in SSc monocytes (p = 0.021), but not in HC monocytes upon TLR8 stimulation. In contrast, the expression of anti-fibrotic Fra1 was significantly (p = 0.037) reduced in SSc monocytes compared to HC. Inhibiting AP-1 activity reduced TIMP-1 production in TLR8 stimulated HC and SSc monocytes. Also, TLR8 stimulation induced significant (p = 0.015) TIMP-1 promoter activity in monocytic U937 cells. Combination of DZNep plus TLR8 enhanced Fra2 (4.1 times) and TIMP-1 (4.7 times) expression in HC monocytes. However, the reverse effect on Fra2 and TIMP-1 expression was observed in SSc monocytes following stimulation. Finally, DZNep plus TLR8-treated HC monocytes induced strong production of collagen and a-SMA in dermal fibroblasts reflecting their trans-differentiation, which is a key event in the pathogenesis of SSc. Conclusions These data demonstrate that histone modification induces by DZNep has an opposite effect of Fra2-mediated TIMP-1 production on HC versus SSc monocytes. Therefore, DZNep cloud be used as a selective regulator of downstream mediators, which orchestrates SSc development.